Which of the following is an example of a Histamine Receptor antagonist that is categorized as B3 for pregnancy safety?

Which of the following is an example of a Histamine Receptor antagonist that is categorized as B3 for pregnancy safety?

• A. Metoclopramide
• B. Cyclizine
• C. Ondansetron
• D. Promethazine

Answer: (B)

Cyclizine is categorized as a Histamine Receptor antagonist that falls under the B3 category for pregnancy safety. This classification indicates that the drug has been shown to pose no risk to the human fetus during studies, making it a safer choice for use in pregnant individuals compared to other antihistamines or antiemetics. Cyclizine specifically works by blocking H1 histamine receptors, which helps to alleviate nausea and vomiting, particularly in situations such as motion sickness or when used as an antiemetic during pregnancy. The B3 classification signifies that there is insufficient evidence of risk, providing additional reassurance for healthcare providers when considering medication options for pregnant patients. Other choices may not have the same safety profile or may not function primarily as H1 antagonists, which makes them less suitable for this particular context of pregnancy safety and nausea management. This distinction is critical when making medication decisions in midwifery practice, ensuring both maternal well-being and fetal safety.

Cyclizine is categorized as a Histamine Receptor antagonist that falls under the B3 category for pregnancy safety. This classification indicates that the drug has been shown to pose no risk to the human fetus during studies, making it a safer choice for use in pregnant individuals compared to other antihistamines or antiemetics.

Cyclizine specifically works by blocking H1 histamine receptors, which helps to alleviate nausea and vomiting, particularly in situations such as motion sickness or when used as an antiemetic during pregnancy. The B3 classification signifies that there is insufficient evidence of risk, providing additional reassurance for healthcare providers when considering medication options for pregnant patients.

Other choices may not have the same safety profile or may not function primarily as H1 antagonists, which makes them less suitable for this particular context of pregnancy safety and nausea management. This distinction is critical when making medication decisions in midwifery practice, ensuring both maternal well-being and fetal safety.